Jon Kyl Brought to You By Exxon : AZ IMC

http://pederson2006.com

Jon Kyl: Brought to you by ExxonHalliburtonGlaxoSmithKlineChevron MerckConocoPfizerAmoco

Sixty percent of American corporations pay no taxes at all, and oil and pharmaceutical companies are making record profits, but Jon Kyl doesn't think that's good enough. He keeps voting Big Oil and Big Pharma big special favors that hurt Arizona families at the pump and at the pharmacy counter, and those companies return the favor with millions in campaign contributions. Click here and here to see how Kyl is voting for the special interests over your interests.
If you want to know what's wrong with Washington, just look at who is financing Jon Kyl's campaign. So far Kyl has received over $5.5 million from Washington special interests.

Kyl has received $310,982 from oil and gas companies and voted 8 times to give tax breaks to Big Oil, while opposing tax incentives for alternative energy.[FEC, opensecrets.org; Vote #553, 10/27/95; Vote #211, 10/11/04; Vote #331, 11/17/05; Vote #332, 11/17/05; Vote #339, 11/17/05; Vote #341, 11/17/05; Vote #345, 11/17/05; Environment and Energy Daily, 04/03/03; Vote 118, 5/11/06]

Kyl, in 2003, Proposed Amendments In The Senate Finance Committee To Eliminate Incentives For Hybrid Cars, Wind Energy, And Alternative Fuels. Kyl, on April 2, 2003, proposed numerous amendments in the Senate Finance Committee. Most were defeated by voice vote, "including one to remove subsidies for wind energy and one to remove subsidies for alternative fuels." [CQ Committee Coverage, 4/2/03]

Kyl Voted to Protect $5 Billion Tax Breaks in Last Year's Energy Bill.When the Senate passed a tax reconciliation bill in February that removed $5 billion in tax breaks for Big Oil, Jon Kyl's Republican Policy Committee urged conferees "to remove these onerous provisions from the final bill." The conferees, which included Kyl, took his advice and put the tax breaks back in the bill. Kyl voted for the final bill with the tax cuts. [Republican Policy Committee, 2/7/06; Washington Post, 4/26/06; CQ Today, 5/1/06; Joint Tax Committee, 5/9/06; Vote 118, 5/11/06]

Kyl Says Benefits of Alternative Fuel Are "Questionable." In 2003, Kyl said, "The benefits of alternative fuel vehicles are questionable." [Environment and Energy Daily, 4/3/03]

Kyl Was the Only Senator to Vote Against Reducing U.S. dependence on Foreign Oil. In June 2003, Kyl voted against an amendment that would require the president to develop and implement measures to reduce total demand for petroleum in the United States by 1 million barrels per day by 2013, with the aim of reducing dependence on foreign oil. It would also require the president to submit an annual progress report to Congress. [S 14, 6/10/03, #213] (Passed 99-1)

Kyl has voted at least 5 times against renewable fuel mandates since 2002. [Vote #77, 4/23/02; Vote #78, 4/23/02; Vote #73 4/29/04; Vote #139, 6/15/05; Vote #88, 4/25/02]

Jon Kyl has Received $ 327,435 from Big Pharma and voted them special favor after special favor. [Opensecrets.org, FEC]

Kyl has repeatedly split with John McCain and voted against allowing safe re-importation of prescription drugs to the U.S. that would have lowered drug costs. [Vote #232, 6/30/03; Vote #179, 7/17/02; Vote #201, 7/31/02]

Kyl cast the deciding vote that prohibited the government from negotiating lower drug prices through Medicare, a bonanza for Big Pharma that's costing taxpayers up to $563 billion. [Vote #60, 3/17/05; Center for Economic and Policy Research, 1/06]

Kyl voted to allow the extension of patents on brand name prescription drugs, shielding them from generic competition, which would drive down prices, for an additional 3 years. Kyl voted for the Hatch, R-Utah, amendment to the Pryor, D-Ark., amendment to allow generic drug companies that made a "substantial investment" prior to the adoption of the General Agreement on Tariffs and Trade (GATT) to develop a generic drug, which GATT extended the patent on, to file under expedited procedures to bring the generic drug to market. The Pryor amendment would have eliminated a provision of the General Agreement on Tariffs and Trade that allows drug companies to extend patents on prescription drugs from 17 to 20 years, thus shielding them from generic drug competition for an additional three years. [Vote #179, 6/27/96]